275 related articles for article (PubMed ID: 14648210)
21. Efficacy of fludarabine/mitoxantrone/dexamethasone alternating with CHOP in bulky follicular non-Hodgkin's lymphoma.
Wilder DD; Ogden JL; Jain VK
Clin Lymphoma; 2002 Mar; 2(4):229-37. PubMed ID: 11970762
[TBL] [Abstract][Full Text] [Related]
22. Biweekly THP-COPBLM (pirarubicin, cyclophosphamide, vincristine, prednisone, bleomycin and procarbazine) regimen combined with granulocyte colony-stimulating factor (G-CSF) for intermediate- and high-grade non-Hodgkins's lymphoma.
Niitsu N; Umeda M
Leukemia; 1998 Sep; 12(9):1457-60. PubMed ID: 9737696
[TBL] [Abstract][Full Text] [Related]
23. Randomized comparison of MACOP-B with CHOP in patients with intermediate-grade non-Hodgkin's lymphoma. The Australian and New Zealand Lymphoma Group.
Cooper IA; Wolf MM; Robertson TI; Fox RM; Matthews JP; Stone JM; Ding JC; Dart G; Matthews J; Firkin FC
J Clin Oncol; 1994 Apr; 12(4):769-78. PubMed ID: 7512131
[TBL] [Abstract][Full Text] [Related]
24. Phase I/II trial of nonpegylated liposomal doxorubicin, cyclophosphamide, vincristine, and prednisone in the treatment of newly diagnosed aggressive non-Hodgkin's lymphoma.
Tulpule A; Espina BM; Berman N; Buchanan LH; Smith DL; Sherrod A; Dharmapala D; Gee C; Boswell WD; Nathwani BN; Welles L; Levine AM
Clin Lymphoma Myeloma; 2006 Jul; 7(1):59-64. PubMed ID: 16879771
[TBL] [Abstract][Full Text] [Related]
25. Biweekly THP-COP therapy for newly diagnosed peripheral T-cell lymphoma patients.
Tomita N; Kodama F; Tsuyama N; Sakata S; Takeuchi K; Ishibashi D; Koyama S; Ishii Y; Yamamoto W; Takasaki H; Hagihara M; Kuwabara H; Tanaka M; Hashimoto C; Yamazaki E; Koharazawa H; Fujimaki K; Sakai R; Fujisawa S; Ishigatsubo Y
Hematol Oncol; 2015 Mar; 33(1):9-14. PubMed ID: 24519501
[TBL] [Abstract][Full Text] [Related]
26. Stage I and II non-Hodgkin's lymphoma: results of combined of THP-COP chemotherapy and radiotherapy.
Ohga S; Nakamura K; Shioyama Y; Sasaki T; Urashima Y; Terashima H; Honda H
Radiat Med; 2005 May; 23(3):156-61. PubMed ID: 15940061
[TBL] [Abstract][Full Text] [Related]
27. Combination chemotherapy with pirarubicin (THP), cyclophosphamide, vincristine, and prednisolone (VEP-THP therapy) in the treatment of non-Hodgkin's lymphoma.
Takagi T; Sakai C; Oguro M
Oncology; 1990; 47(1):25-8. PubMed ID: 2300381
[TBL] [Abstract][Full Text] [Related]
28. Comparison of CHOP with THP-COP for peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma: a retrospective analysis using data from the population-based Osaka Cancer Registry.
Kida S; Fuji S; Morishima T; Nakata K; Miyashiro I; Ishikawa J
Int J Hematol; 2021 Aug; 114(2):246-251. PubMed ID: 33864237
[TBL] [Abstract][Full Text] [Related]
29. [Comparison of chemotherapy CHOP vs. CHOP/VIA in the treatment of aggressive non-Hodgkin's lymphoma: a randomized multicenter study of 132 patients. The PETHEMA group. Program for Study and Therapeutics of malignant hemopathies. Spanish Association of Hematology and Hemotherapy].
López-Guillermo A; García-Conde J; Alvarez-Carmona AM; León P; Maldonado J; Alcalá A; Zubizarreta A; Sancho-Tello R; Carbonell F; Contreras E; Besses C; Hernando A; Fontanillas M; Montserrat E
Med Clin (Barc); 1998 May; 110(16):601-4. PubMed ID: 9656196
[TBL] [Abstract][Full Text] [Related]
30. A randomized EPOCH vs. CHOP front-line therapy for aggressive non-Hodgkin's lymphoma patients: long-term results.
Khaled HM; Zekri ZK; Mokhtar N; Ali NM; Darwish T; Elattar I; Gaafar R; Moawad MS
Ann Oncol; 1999 Dec; 10(12):1489-92. PubMed ID: 10643541
[TBL] [Abstract][Full Text] [Related]
31. MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group.
Sertoli MR; Santini G; Chisesi T; Congiu AM; Rubagotti A; Contu A; Salvagno L; Coser P; Porcellini A; Vespignani M
J Clin Oncol; 1994 Jul; 12(7):1366-74. PubMed ID: 7517442
[TBL] [Abstract][Full Text] [Related]
32. High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin's lymphoma: a dose-finding pilot study.
Shipp MA; Neuberg D; Janicek M; Canellos GP; Shulman LN
J Clin Oncol; 1995 Dec; 13(12):2916-23. PubMed ID: 8523055
[TBL] [Abstract][Full Text] [Related]
33. A phase II study of rituximab combined with pirarubicin-cyclophosphamide, vincristine and prednisolone regimen as first-line therapy for patients with indolent B-cell lymphoma.
Tsurumi H; Hara T; Goto N; Kitagawa J; Kanemura N; Yoshikawa T; Kasahara S; Goto H; Fukuno K; Yamada T; Sawada M; Shimizu M; Takahashi T; Takami T; Moriwaki H
Leuk Lymphoma; 2012 Feb; 53(2):247-53. PubMed ID: 21827339
[TBL] [Abstract][Full Text] [Related]
34. Liposomal daunorubicin (DaunoXome) in combination with cyclophosphamide, vincristine and prednisolone (COP-X) as salvage therapy in poor-prognosis non-Hodgkins lymphoma.
McBride NC; Cavenagh JD; Ward MC; Grant I; Schey S; Gray A; Hughes A; Mills MJ; Cervi P; Newland AC; Kelsey SM
Leuk Lymphoma; 2001 Jun; 42(1-2):89-98. PubMed ID: 11699226
[TBL] [Abstract][Full Text] [Related]
35. Long-term results of a multicentre randomised, comparative phase III trial of CHOP versus CNOP regimens in patients with intermediate- and high-grade non-Hodgkin's lymphomas. Novantrone International Study Group.
Bezwoda W; Rastogi RB; Erazo Valla A; Diaz-Maqueo JC; Pavlovsky S; Morioka H; Resegotti L; Rueckle H; Somoza N; Moreno-Nogueira JA
Eur J Cancer; 1995 Jun; 31A(6):903-11. PubMed ID: 7646919
[TBL] [Abstract][Full Text] [Related]
36. Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19).
Herold M; Schulze A; Niederwieser D; Franke A; Fricke HJ; Richter P; Freund M; Ismer B; Dachselt K; Boewer C; Schirmer V; Weniger J; Pasold R; Winkelmann C; Klinkenstein C; Schulze M; Arzberger H; Bremer K; Hahnfeld S; Schwarzer A; Müller C; Müller C;
J Cancer Res Clin Oncol; 2006 Feb; 132(2):105-12. PubMed ID: 16088404
[TBL] [Abstract][Full Text] [Related]
37. Results of a randomized study of previously-untreated intermediate and high grade lymphoma using CHOP versus CNOP.
Pavlovsky S; Santarelli MT; Erazo A; Diaz Maqueo JC; Somoza N; Lluesma Goñalons M; Cervantes G; Garcia Vela EL; Corrado C; Magnasco H
Ann Oncol; 1992 Mar; 3(3):205-9. PubMed ID: 1586618
[TBL] [Abstract][Full Text] [Related]
38. Elderly patients with aggressive non-Hodgkin's lymphoma: disease presentation, response to treatment, and survival--a Groupe d'Etude des Lymphomes de l'Adulte study on 453 patients older than 69 years.
Bastion Y; Blay JY; Divine M; Brice P; Bordessoule D; Sebban C; Blanc M; Tilly H; Lederlin P; Deconinck E; Salles B; Dumontet C; Brière J; Coiffier B
J Clin Oncol; 1997 Aug; 15(8):2945-53. PubMed ID: 9256139
[TBL] [Abstract][Full Text] [Related]
39. Adding high-dose tamoxifen to CHOP does not influence response or survival in aggressive non-Hodgkin's lymphoma: an interim analysis of a randomized phase III trial.
Ezzat AA; Ibrahim EM; Stuart RK; Ajarim D; Bazarbashi S; El-Foudeh MO; Rahal M; Al-Sayed A; Berry J
Med Oncol; 2000 Feb; 17(1):39-46. PubMed ID: 10713659
[TBL] [Abstract][Full Text] [Related]
40. THP-COPBLM (pirarubicin, cyclophosphamide, vincristine, prednisone, bleomycin and procarbazine) regimen combined with granulocyte colony-stimulating factor (G-CSF) for non-Hodgkin's lymphoma in elderly patients: a prospective study.
Niitsu N; Umeda M
Leukemia; 1997 Nov; 11(11):1817-20. PubMed ID: 9369412
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]